Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMOFlipid Safety Study for EFAD and PNAC in Patients Needing Long-term Parenteral Nutrition
NCT06049680Phase 4Recruiting
- Sponsor
- Fresenius Kabi
- Start
- Oct 2024
- Primary completion
- Nov 2026
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 4 trial of SMOFlipid in Malnutrition, essential fatty acid deficiency (EFAD), parenteral nutrition-associated cholestasis (PNAC), sponsored by Fresenius Kabi. Started Oct 2024; status: recruiting.
02
Drugs
SMOFlipid
03
Conditions
Malnutritionessential fatty acid deficiency (EFAD)parenteral nutrition-associated cholestasis (PNAC)
Beyond the preview
Go deeper on NCT06049680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06049680.